Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in ...
Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has received a consensus rating of “Buy” from the seven ratings firms that ...
Royalty Pharma plc's ( NASDAQ:RPRX) periodic dividend will be increasing on the 10th of March to $0.22, with investors receiving 4.8% more than last year's $0.21. The payment will take the dividend ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback